Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Reata Pharma (RETA)
Reata Pharma (RETA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,515,149
  • Shares Outstanding, K 37,551
  • Annual Sales, $ 2,220 K
  • Annual Income, $ -311,900 K
  • 60-Month Beta 1.52
  • Price/Sales 1,591.68
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade RETA with:

Options Overview Details

View History
  • Implied Volatility 53.95% ( -4.94%)
  • Historical Volatility 74.01%
  • IV Percentile 4%
  • IV Rank 2.71%
  • IV High 412.97% on 02/27/23
  • IV Low 43.96% on 03/29/23
  • Put/Call Vol Ratio 0.15
  • Today's Volume 571
  • Volume Avg (30-Day) 2,491
  • Put/Call OI Ratio 1.10
  • Today's Open Interest 33,038
  • Open Int (30-Day) 40,132

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -2.66
  • Number of Estimates 3
  • High Estimate -2.34
  • Low Estimate -3.08
  • Prior Year -2.02
  • Growth Rate Est. (year over year) -31.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.54 +22.94%
on 05/10/23
106.69 -11.80%
on 05/09/23
-10.68 (-10.19%)
since 05/08/23
3-Month
76.54 +22.94%
on 05/10/23
106.69 -11.80%
on 05/09/23
+10.14 (+12.08%)
since 03/08/23
52-Week
18.47 +409.47%
on 08/17/22
106.69 -11.80%
on 05/09/23
+59.34 (+170.71%)
since 06/08/22

Most Recent Stories

More News
RETA INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.

/PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Reata Pharmaceuticals, Inc. ("Reata") (NASDAQ: RETA) concerning...

RETA : 94.10 (+0.52%)
RETA ALERT: The Law Offices of Vincent Wong Investigate Reata Pharmaceuticals, Inc. for Potential Violations of Securities Laws

/PRNewswire/ -- Attention Reata Pharmaceuticals, Inc. ("Reata") (NASDAQ: RETA) shareholders: The Law Offices of Vincent Wong announce that an investigation has...

RETA : 94.10 (+0.52%)
RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

/PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Reata...

RETA : 94.10 (+0.52%)
RETA INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.

/PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Reata Pharmaceuticals, Inc. ("Reata") (NASDAQ: RETA) concerning...

RETA : 94.10 (+0.52%)
RETA NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.

/PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Reata Pharmaceuticals, Inc. ("Reata") (NASDAQ: RETA) violated federal...

RETA : 94.10 (+0.52%)
RETA ALERT: The Law Offices of Vincent Wong Investigate Reata Pharmaceuticals, Inc. for Potential Violations of Securities Laws

/PRNewswire/ -- Attention Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASDAQ: RETA) shareholders: The Law Offices of Vincent Wong announce that an...

RETA : 94.10 (+0.52%)
RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

/PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Reata...

RETA : 94.10 (+0.52%)
RETA NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.

/PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASDAQ: RETA)...

RETA : 94.10 (+0.52%)
RETA INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.

/PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Reata Pharmaceuticals, Inc. ("Reata" or "the Company") (NASDAQ:...

RETA : 94.10 (+0.52%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reata Pharmaceuticals, Inc. - RETA

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA). Such...

RETA : 94.10 (+0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Reata Pharmaceuticals is a clinical-stage pharmaceutical company primarily focused on discovering, developing and commercializing small-molecule based innovative therapies for treating severe, life-threatening diseases with a few or no approved therapies. The company is developing its lead pipeline candidates...

See More

Key Turning Points

3rd Resistance Point 97.10
2nd Resistance Point 96.15
1st Resistance Point 95.12
Last Price 94.10
1st Support Level 93.14
2nd Support Level 92.19
3rd Support Level 91.16

See More

52-Week High 106.69
Last Price 94.10
Fibonacci 61.8% 72.99
Fibonacci 50% 62.58
Fibonacci 38.2% 52.17
52-Week Low 18.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar